Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 1
2000 4
2001 4
2002 2
2003 3
2004 2
2005 3
2006 2
2007 6
2008 3
2009 3
2010 5
2012 7
2013 3
2014 2
2015 3
2016 4
2017 2
2018 3
2019 1
2020 3
2021 7
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Biologic Therapy in Rare Eosinophil-Associated Disorders: Remaining Questions and Translational Research Opportunities.
Khoury P, Roufosse F, Kuang FL, Ackerman SJ, Akuthota P, Bochner BS, Johansson MW, Mathur SK, Ogbogu PU, Spencer LA, Wechsler ME, Zimmermann N, Klion AD; International Eosinophil Society Clinical Research Interest Group. Khoury P, et al. Among authors: roufosse f. J Leukoc Biol. 2024 Mar 8:qiae051. doi: 10.1093/jleuko/qiae051. Online ahead of print. J Leukoc Biol. 2024. PMID: 38457125
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. Among authors: roufosse f. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
HES and EGPA: Two Sides of the Same Coin.
Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F. Khoury P, et al. Among authors: roufosse f. Mayo Clin Proc. 2023 Jul;98(7):1054-1070. doi: 10.1016/j.mayocp.2023.02.013. Mayo Clin Proc. 2023. PMID: 37419574 Free article. Review.
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.
J Jackson D, Akuthota P, Andradas R, J Bredenoord A, Cordell A, Gray S, Kullman J, Mathur SK, Pavord I, Roufosse F, Rubio C, Rusek IC, Simon D, Strobel MJ, Winders T. J Jackson D, et al. Among authors: roufosse f. Immunotherapy. 2023 May 17. doi: 10.2217/imt-2022-0312. Online ahead of print. Immunotherapy. 2023. PMID: 37194573 Free article. Review.
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Valent P, et al. Among authors: roufosse f. Allergy. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544. Epub 2022 Oct 19. Allergy. 2023. PMID: 36207764 Free PMC article. Review.
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N; HES Mepolizumab Study Group. Rothenberg ME, et al. Among authors: roufosse f. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2367-2374.e3. doi: 10.1016/j.jaip.2022.04.037. Epub 2022 May 12. J Allergy Clin Immunol Pract. 2022. PMID: 35568330 Free article. Clinical Trial.
85 results